Program
Lamotrigine
Also written as “lamotrigine”, “Lamotrigine Tablets 25 mg” and “Lamictal”.
Its studies are mostly in Epilepsy · Bipolar Disorder · Epilepsy, Tonic-Clonic · Epilepsies, Partial · Schizophrenia, led by 9 companies.
Drug pageLamotrigine: every studyMany companies study it; this page follows only the 54 they lead. All 137 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| GlaxoSmithKlineits history only | 330 open or running | phase 4since Aug 14, 2002 | Aug 14, 2002 | none ahead |
| Dr. Reddy's Laboratoriesits history only | 80 open or running | phase 1since May 26, 2010 | May 26, 2010 | none ahead |
| Teva Pharmaceutical Industriesits history only | 40 open or running | phase 1since Jan 30, 2009 | Jan 30, 2009 | none ahead |
| IPCA Laboratoriesits history only | 20 open or running | phase 1since Jun 11, 2012 | Jun 11, 2012 | none ahead |
| Torrent Pharmaceuticalsits history only | 20 open or running | phase 1since Jul 13, 2009 | Jul 13, 2009 | none ahead |
| Viatrisits history only | 20 open or running | phase 1since Mar 30, 2008 | Mar 30, 2008 | none ahead |
| Alembic Pharmaceuticalsits history only | 10 open or running | phase 1since Jan 9, 2018 | Jan 9, 2018 | none ahead |
| Desitin Arzneimittelits history only | 10 open or running | phase 1since Dec 12, 2023 | Dec 12, 2023 | none ahead |
| Pharmtechnology | 10 open or running | phase 1since Mar 29, 2019 | Mar 29, 2019 | none ahead |
Also a collaborator on its studies: BioPharma Services.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Pharmtechnology only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Mar 29, 2019First study: phase 1 study in Healthy AdultsFirst studyNCT03898011 · 28 enrolled · Russian Federation
TargetBeta
“Sodium channel alpha subunit blocker”ChEMBL 37, by rule
Other programs on the same 10 targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Lidocainerule | Keenova Therapeutics | phase 4 | 63 |
| Carbamazepinerule | grin-therapeutics-inc | phase 4 | 21 |
| Dronedaronerule | Sanofi | phase 4 | 18 |
| chloroprocainerule | sintetica-sa | phase 4 | 8 |
| Riluzolerule | Sanofi | phase 4 | 6 |
| Prilocainerule | Haisco Pharmaceutical Group | phase 4 | 2 |
| Carticainerule | Laboratoires Thea | phase 4 | 1 |
| Ropivacainerule | painreform-ltd | phase 3 | 17 |
| Quinidinerule | Otsuka | phase 3 | 17 |
| Phenytoinrule | Viatris | phase 3 | 10 |
| rufinamiderule | Eisai | phase 3 | 7 |
Studies
The one study Pharmtechnology leads. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT03898011Healthy Adults · Russian Federation | 1 | Completed | May 4, 2019 | 28 |
How it is read
Names in the registry
- “Lamotrigine”, 26 entries
- “lamotrigine”, 12 entries
- “Lamotrigine Tablets 25 mg”, 4 entries
- “Lamictal”, 3 entries
- “Lamotrigine 25 mg Chewable Tablets”, 2 entries
Conditions, from the studies’ own filings
- Epilepsy, 17 studies
- Bipolar Disorder, 11 studies
- Epilepsy, Tonic-Clonic, 2 studies
- Epilepsies, Partial, 2 studies
- Schizophrenia, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.